These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 11004330

  • 1. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 2. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C, Onal Y, Sager S, Asa S, Ustabasioglu FE, Alis D, Akman C, Sonmezoglu K.
    Curr Med Imaging Rev; 2019 Dec; 15(10):956-964. PubMed ID: 32008523
    [Abstract] [Full Text] [Related]

  • 11. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 12. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma.
    Lips P, Comans EF, Hoekstra OS, van der Poest Clement E, van Mourik JC, Teule GJ.
    Neth J Med; 2000 Oct; 57(4):150-6. PubMed ID: 11006491
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R.
    Rev Esp Med Nucl; 2005 Oct; 24(1):5-13. PubMed ID: 15701340
    [Abstract] [Full Text] [Related]

  • 15. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [Abstract] [Full Text] [Related]

  • 16. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC, Ng DC, Sundram FX.
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
    Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F.
    Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
    [Abstract] [Full Text] [Related]

  • 19. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.